Citations

Clear

959 citation(s) found for "Service, F J".

Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis — United States
Biggs, Holly M. , Behravesh, Casey Barton , Bradley, Kristy, Dahlgren, F. Scott , Drexler, Naomi A. , Dumler, J. Stephen , Folk, Scott M., Kato, Cecilia Y. , Lash, R. Ryan , Levin, Michael L. , Massung, Robert F., Nadelman, Robert B., Nicholson, William L. , Paddock, Christopher D., Pritt, Bobbi S. , Traeger, Marc, Paddock, Christopher D. , Pritt, Bobbi S

Mayo Clinic

MMWR. Recommendations and Reports | May 12, 2016 | Volume: 65 | Issue: 2 | Pages: 1-44

10.15585/mmwr.rr6502a1 | PMID 27172113 Get It

Introducing routine HIV screening for patients on an internal medicine residency inpatient service: a quality improvement project
Padrnos, Leslie , Barr, Patrick J, Klassen, Christine L. , Fields, Heather , Azadeh, Natalya , Mendoza, N. S., Pauwels, Emanuel M, King, Christopher S. , Chung, Andrew A., Sakata, Kenneth K. , Blair, Janis E. , Padrnos, Leslie J, Fields, Heather E, Mendoza, Neil, Saadiq, Rayya A. , Mendoza, N. S.

Mayo Clinic

BMJ Quality Improvement Reports | May 5, 2016 | Volume: 5 | Issue: 1 | Pages: u206955.w3030

10.1136/bmjquality.u206955.w3030 | PMID 27239302 Get It

The US Centers for Disease Control and Prevention (CDC) recommend human immunodeficiency virus (HIV) screening for all persons aged 13 to 64 years who present to a health care provider. We sought to improve adherence to the CDC guidelines on the Internal Medicine Resident Hospital Service. We surveyed residents about the CDC guidelines, sent email reminders, provided education, and engaged them in friendly competition. Credit for guideline adherence was awarded if an offer of HIV screening was documented at admission, if a screening test was performed, or if a notation in the resident sign out sheet indicated why screening was not performed. We examined HIV screening of a postintervention group of patients admitted between August 8, 2012, and June 30, 2013, and compared them to a preintervention group admitted between August 1, 2011, and June 30, 2012. Postintervention offers of HIV screening increased significantly (7.9% [44/559] vs 55.5% [300/541]; P<.001), as did documentation of residents' contemplation of screening (8.9% [50/559] vs 67.5% [365/541]; P<.001). A significantly higher proportion of HIV screening tests was ordered postintervention (7.7% [43/559] vs 44.4% [240/541]; P<.001). Monthly HIV screening documentation ranged from 0% (0/53) to 17% (9/53) preintervention, whereas it ranged from 30.6% (11/36) to 100% (62/62) postintervention. HIV screening adherence can be improved through resident education, friendly competition, and system reminders. Barriers to achieving sustained adherence to the CDC guidelines include a heterogeneous patient population and provider discomfort with the subject.
Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study
Jayasekara, Harindra , Reece, Jeanette C. , Buchanan, Daniel D. , Rosty, Christophe , Dashti, S. Ghazaleh , Ouakrim, Driss Ait , Winship, Ingrid , Boussioutas, Alex , Giles, Graham G. , Ahnen, Dennis J. , Lowery, Jan T. , Haile, Robert W. , Gallinger, Steven, Lindor, Noralane M. , Parry, Susan, Jenkins, Mark A. , Win, Aung Ko , Macrae, Finlay , Casey, Graham , Marchand, Loı̈c Le , Newcomb, Polly A. , Hopper, John L. , Buchanan, Daniel D , Win, Aung K , Giles, Graham G , Jenkins, Mark A , Haile, Robert W , Rosty, Christophe , Winship, Ingrid M , Jayasekara, Harindra

Mayo Clinic

International Journal of Cancer | April 21, 2016 | Volume: 139 | Issue: 5 | Pages: 1081-1090

10.1002/ijc.30153 | PMID 27098183 Get It

Individuals diagnosed with colorectal cancer (CRC) are at risk of developing a metachronous CRC. We examined the associations between personal, tumour‐related and lifestyle risk factors, and risk of metachronous CRC. A total of 7,863 participants with incident colon or rectal cancer who were recruited in the USA, Canada and Australia to the Colon Cancer Family Registry during 1997‐2012, except those identified as high‐risk, for example, Lynch syndrome, were followed up approximately every 5 years. We estimated the risk of metachronous CRC, defined as the first new primary CRC following an interval of at least one year after the initial CRC diagnosis. Observation time started at the age at diagnosis of the initial CRC and ended at the age at diagnosis of the metachronous CRC, last contact or death whichever occurred earliest, or were censored at the age at diagnosis of any metachronous colorectal adenoma. Cox regression was used to derive hazard ratios (HRs) and 95% confidence intervals (CIs). During a mean follow‐up of 6.6 years, 142 (1.81%) metachronous CRCs were diagnosed (mean age at diagnosis 59.8; incidence 2.7/1,000 person‐years). An increased risk of metachronous CRC was associated with the presence of a synchronous CRC (HR = 2.73; 95% CI: 1.30–5.72) and the location of cancer in the proximal colon at initial diagnosis (compared with distal colon or rectum, HR = 4.16; 95% CI: 2.80–6.18). The presence of a synchronous CRC and the location of the initial CRC might be useful for deciding the intensity of surveillance colonoscopy for individuals diagnosed with CRC.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Sonneveld, Pieter , Avet‐Loiseau, Hervé , Usmani, Saad Z. , Moreau, Philippe , Attal, Michel , Kyle, Robert A. , Caers, Jo , Hillengaß, Jens , Miguel, Jesús F. San , Donk, Niels W.C.J. van de , Bladé, Joan , Durie, Brian G.M. , Goldschmidt, Hartmut , Mateos, María‐Victoria , Palumbo, Antonio , Orlowski, Robert Z. , Lonial, Sagar , Siegel, David S. , Anderson, Kenneth C. , Chng, Wee Joo , Einsele, Hermann , Orlowski, Robert Z. , Moreau, Philippe , San-Miguel, Jesus , Usmani, Saad

Mayo Clinic

Blood | March 22, 2016 | Volume: 127 | Issue: 24 | Pages: 2955-2962

10.1182/blood-2016-01-631200 | PMID 27002115 Get It

AbstractThe International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Dimopoulos, Meletios Α. , Sonneveld, Pieter , Merlini, Giampaolo , Kastritis, Efstathios , Goldschmidt, Hartmut , Joshua, Douglas, Orlowski, Robert Z. , Powles, Raymond, Vesole, David H., Garderet, Laurent, Palumbo, Antonio , Cavo, Michèle , Richardson, Paul G. , Moreau, Philippe , Miguel, Jesús F. San , Durie, Brian G.M. , Terpos, Evangelos , Bergsagel, P. Leif , Russell, Stephen J. , Rosiñol, Laura , Ocio, Enrique M. , García‐Sánz, Ramón , Beksaç, Meral , Zweegman, Sonja , Usmani, Saad Z. , Donk, Niels W.C.J. van de , Pratt, Guy , Chari, Ajai , Cook, Gordon , Rossi, Adriana , O’Dwyer, Michael , Paiva, Bruno , Larrea, Carlos Fernández de , Souza, Cármino Antônio De , Terragna, Carolina , Bergsagel, P. Leif , Dimopoulos, Meletios A, Ludwig, Heinz , San Miguel, Jesús, Leung, Nelson , Joshua, Douglas, Orlowski, Robert Z. , Einsele, Hermann , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Zweegman, Sonja , Merlini, Giampaolo , Dimopoulos, Meletios A , Russell, Stephen J , Moreau, Philippe , Terpos, Evangelos , Chari, Ajai , San-Miguel, Jesus , Paiva, Bruno , Kastritis, Efstathios , Garcia-Sanz, Ramon , Beksac, Meral , Cook, Gordon , Usmani, Saad , Rossi, Adriana , Ocio, Enrique M

Mayo Clinic

Journal of Clinical Oncology | March 14, 2016 | Volume: 34 | Issue: 13 | Pages: 1544-1557

10.1200/jco.2015.65.0044 | PMID 26976420 Get It

Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m 2 to 140 mg/m 2 ) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Emile, Jean‐François , Abla, Oussama , Fraitag, Sylvie , Horne, AnnaCarin , Haroche, Julien , Requena‐Caballero, Luis, Jordan, Michael B. , Allen, Carl E. , Charlotte, Frédéric , Egeler, R. Maarten , Herrera, Juana Gil, Henter, Jan‐Inge , Jankú, Filip , Mérad, Miriam , Rollins, Barret J., Tazi, Abdellatif , Vassallo, Robert , Weiss, Lawrence M. , Astigarraga, Itziar , Donadieu, Jean , Abdel‐Wahab, Omar , Diamond, Eli L. , Fischer, Alain , Picarsic, Jennifer , Rodríguez‐Galindo, Carlos , Vassallo, Robert , Emile, Jean-François , Allen, Carl E

Mayo Clinic

Blood | March 10, 2016 | Volume: 127 | Issue: 22 | Pages: 2672-2681

10.1182/blood-2016-01-690636 | PMID 26966089 Get It

Abstract The histiocytoses are rare disorders characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs of children and adults. More than 100 different subtypes have been described, with a wide range of clinical manifestations, presentations, and histologies. Since the first classification in 1987, a number of new findings regarding the cellular origins, molecular pathology, and clinical features of histiocytic disorders have been identified. We propose herein a revision of the classification of histiocytoses based on histology, phenotype, molecular alterations, and clinical and imaging characteristics. This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Herein, we provide guidelines and recommendations for diagnoses of these disorders.
Peer review fraud—it's not big and it's not clever
Rahman, Shamima , Baumgartner, Matthias R. , Patterson, Marc C. , Peters, Verena, Zschocke, Johannes , Patterson, Marc, Morava, Éva , Patterson, Marc , Baumgartner, Matthias

Mayo Clinic

Journal of Inherited Metabolic Disease | December 11, 2015 | Volume: 39 | Issue: 1 | Pages: 1-2

10.1007/s10545-015-9905-x | PMID 26660661 Get It

Optimization and Simulation of Orthopedic Spine Surgery Cases at Mayo Clinic
Ozen, Asli, Marmor, Yariv N. , Rohleder, Thomas R., Balasubramanian, Hari , Huddleston, Jeanne M. , Huddleston, P.M. , Huddleston, Paul M

Mayo Clinic

Manufacturing & Service Operations Management | November 20, 2015 | Volume: 18 | Issue: 1 | Pages: 157-175

10.1287/msom.2015.0564 Get It

Spine surgeries tend to be lengthy (mean time of 4 hours) and highly variable (with some surgeries lasting 18 hours or more). This variability along with patient preferences driving scheduling decisions resulted in both low operating room (OR) utilization and significant overtime for surgical teams at Mayo Clinic. In this paper we discuss the development of an improved scheduling approach for spine surgeries over a rolling planning horizon. First, data mining and statistical analysis was performed using a large data set to identify categories of surgeries that could be grouped together based on surgical time distributions and could be categorized at the time of case scheduling. These surgical categories are then used in a hierarchical optimization approach with the objective of maximizing a weighted combination of OR utilization and net profit. The optimization model is explored to consider trade-offs and relationships among utilization levels, financial performance, overtime allowance, and case mix. The new scheduling approach was implemented via a custom Web-based application that allowed the surgeons and schedulers to interactively identify best surgical days with patients. A pilot implementation resulted in a utilization increase of 19% and a reduction in overtime by 10%.
Subcutaneous infusion of kisspeptin‐54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels
Narayanaswamy, Shakunthala, Jayasena, Channa , Ng, Noel , Ratnasabapathy, Risheka , Prague, Julia , Papadopoulou, Deborah , Abbara, Ali , Comninos, Alexander , Bassett, Paul , Bloom, Stephen R. , Veldhuis, Johannes D. , Dhillo, Waljit S. , Jayasena, Channa N

Mayo Clinic

Clinical Endocrinology | November 17, 2015 | Volume: 84 | Issue: 6 | Pages: 939-945

10.1111/cen.12977 | PMID 26572695 Get It

SummaryBackground and objectiveKisspeptin stimulates hypothalamic GnRH secretion resulting in gonadotrophin release and has potential as a future therapeutic. Chronic subcutaneous infusion of kisspeptin via a pump (similar to an insulin pump) may provide an alternative route of administration in the future. We investigated for the first time in humans, the gonadotrophin response to subcutaneous (SC) infusions of kisspeptin‐54 in healthy women. Women are markedly more responsive to exogenous kisspeptin in the late follicular phase preovulation when oestradiol levels are naturally high. Therefore, we further investigated whether there was a correlation between baseline oestradiol levels and LH response to kisspeptin.Design and patientsA prospective, single‐blinded placebo‐controlled study. Healthy women (n = 4) received an 8‐h SC infusion of kisspeptin‐54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles. Gonadotrophins and oestradiol were measured every 10 min during the infusions.ResultsSC infusion of kisspeptin‐54 increased LH and FSH. The LH response to SC infusion of kisspeptin‐54 (0·3 and 1·0 nmol/kg/h) positively correlated with baseline oestradiol levels (P < 0·001). Further statistical analyses showed that in the 1·0 nmol/kg/h group, a 100pmol/l rise in baseline oestradiol was associated with a 1·0 IU/l increase in LH.ConclusionsKisspeptin administered via a SC infusion could be a viable future therapeutic route of administration for patients with infertility. Baseline oestradiol levels may be an important determinant of the gonadotrophin response to kisspeptin treatment in women and should be taken into consideration when evaluating gonadotrophin response.
Values as Hypotheses: Design, Inquiry, and the Service of Values
JafariNaimi, Nassim, Nathan, Lisa P. , Hargraves, Ian

Mayo Clinic

Design Issues | October 6, 2015 | Volume: 31 | Issue: 4 | Pages: 91-104

10.1162/desi_a_00354 Get It